Table 5 Baseline clinical characteristics of patients in different β2-MG groups in validation cohort A
Ln(β2-MG/uCr) | Low tertile (≤ 2.45) | High tertile (> 2.45) | |
|---|---|---|---|
Variable | N = 56 | N = 55 | OR (95% CI) |
No response (%) | 5 (8.9) | 29 (52.7) | 11.38 (3.94–32.84)# |
Age (year) | 33.0 ± 14.2 | 38.0 ± 15.9 | 1.02 (0.997–1.05) |
Gender (%) male | 33 (58.9) | 32 (58.2) | 1.03 (0.49–2.20) |
MAP (mmHg) | 92.1 ± 10.8 | 94.3 ± 18.9 | 1.01 (0.99–1.04) |
BMI (kg/m2) | 23.7 ± 3.8 | 24.9 ± 3.9 | 1.08 (0.97–1.21) |
Ln(Pro) (g/24 h) | 1.8 ± 0.4 | 1.8 ± 0.4 | 1.06 (0.45–2.46) |
Albumin (g/L) | 16.5 ± 5.2 | 16.4 ± 7.0 | 0.996 (0.94–1.06) |
eGFR (mL/min/1.73 m2) | 100.9 ± 23.5 | 86.0 ± 39.0 | 0.99 (0.97–0.998)* |
TG (mmol/L) | 2.9 ± 2.4 | 4.4 ± 4.2 | 1.20 (1.002–1.44)* |
TC (mmol/L) | 10.0 ± 3.7 | 11.1 ± 4.9 | 1.06 (0.97–1.17) |
Interstitial fibrosis (%) | 25 (44.6) | 39 (70.9) | 3.02 (1.387–6.63)# |
Inflammatory cell infiltration (%) | 21 (37.5) | 33 (60.0) | 2.50 (1.16–5.37)* |
Tubular atrophy (%) | 24 (42.9) | 33 (60.0) | 2.00 (0.94–4.26) |